Arvinas Inc. (NASDAQ:ARVN), a biotechnology company specializing in protein degradation therapeutics, stands at a critical juncture as it approaches the release of pivotal clinical trial data.

President Donald Trump's 25% tariff plan on goods from Canada and Mexico rattled markets early Monday. Follow along for live ...

Nifty 50 Today Live Updates on February 3, 2025: At 16:45 Nifty 50 was trading at 23361.05 (-0.52%). Today Nifty 50 has been ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter ...

NewAmsterdam Pharma saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 80 to 83. Please ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Growth stocks can be a good way to build wealth. These are some of the best growth stocks for February 2025 ...

Shares of Cameco Co. (TSE:CCO – Get Free Report) (NYSE:CCJ) have been assigned a consensus recommendation of “Buy” from the ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.